Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Completed No phase listed Observational

Psychosocial Impact of Cancer-Related Female Infertility

NCT00386217
View directory record Official record
Conditions
Hodgkin's Disease, Cervical Cancer, Breast Cancer, Lymphoma
Interventions
Telephone Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
14 Years and older · Female only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 28, 2026, 8:39 PM EDT
Not listed Not applicable Interventional

UCLA Breast Cancer Survivor Health Promotion Research Study

NCT05113485
View directory record Official record
Conditions
Breast Cancer
Interventions
Diabetes Prevention Program-based lifestyle change intervention (DPP), Highly Microbiota-Accessible Foods (HMAFs) intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 28, 2026, 8:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding the Value of Community Vital Signs in Primary Care

NCT02512835
View directory record Official record
Conditions
Colon Cancer, Breast Cancer, Cervical Cancer, Prostate Cancer, Cardiovascular Disease
Interventions
Community vital signs
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Fairfax, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 28, 2026, 8:39 PM EDT
Not listed Phase 2 Interventional

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

NCT05453825
View directory record Official record
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions
navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy
Biological
Lead sponsor
OncXerna Theraputics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 28, 2026, 8:39 PM EDT
Terminated Phase 1Phase 2 Interventional

GEN1047 for Solid Tumors - First in Human (FIH) Trial

NCT05180474
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)
Interventions
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 28, 2026, 8:39 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

NCT02778685
View directory record Official record
Conditions
Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Fulvestrant, Laboratory Biomarker Analysis, Letrozole, Palbociclib, Pembrolizumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Corona, California • Duarte, California • Lancaster, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Phase 2 Interventional Results available

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

NCT00530868
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast, Breast Neoplasm
Interventions
Letrozole (Femara), Letrozole; Avastin
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 28, 2026, 8:39 PM EDT
Terminated Phase 1 Interventional

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

NCT07408089
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
BBI-940, Fulvestrant
Drug
Lead sponsor
Boundless Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Los Angeles, California • Lake Success, New York • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Phase 1 Interventional

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

NCT00019435
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
Interventions
LMB-9 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel in Node Positive Adjuvant Breast Cancer

NCT00688740
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, 5-fluorouracil, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 16, 2011 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

NCT03058289
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
Interventions
INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
Drug · Biological
Lead sponsor
Intensity Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 28, 2026, 8:39 PM EDT
Terminated Not applicable Interventional

Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy

NCT01821768
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sentinel Lymph Node Biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Not applicable Interventional

Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer

NCT01290835
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereotactic radiotherapy delivered by CyberKnife, stereotactic radiotherapy
Radiation
Lead sponsor
Essentia Health
Other
Eligibility
60 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 28, 2026, 8:39 PM EDT
Not listed Phase 2 Interventional

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

NCT02939274
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Verteporfin, Continuous Low-Irradiance Photodynamic Therapy (CLIPT)
Drug · Device
Lead sponsor
Rogers Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions

NCT00721435
View directory record Official record
Conditions
Breast Cancer, Mass Cystic, Benign Mass
Interventions
3D Tomosynthesis and ultrasound imaging
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
25 Years and older · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Phase 2 Interventional

Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

NCT00043017
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI/MRS, gadopentetate dimeglumine
Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Mammography FastTrack Program in Increasing the Number of Women Undergoing Breast Cancer Screening

NCT00462891
View directory record Official record
Conditions
Breast Cancer
Interventions
IT System
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
6,730 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 28, 2026, 8:39 PM EDT
Recruiting Phase 1 Interventional

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer

NCT05412225
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer
Interventions
Pre-neoadjuvant radiotherapy (NART) biopsy, Neoadjuvant radiotherapy, Unilateral total mastectomy with axillary lymph node dissection
Diagnostic Test · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Not applicable Interventional

Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study

NCT00597532
View directory record Official record
Conditions
Breast Cancer
Interventions
Soy, Milk
Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

NCT01355393
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim, rintatolimod
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 28, 2026, 8:39 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

NCT00623233
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Interventions
Gemcitabine, Bevacizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Fayetteville, Arkansas • Fresno, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Oct 28, 2026, 8:39 PM EDT
Recruiting Phase 2 Interventional

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

NCT04305834
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Abemaciclib, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
70 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Long Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 8:39 PM EDT
Recruiting Not applicable Interventional

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy

NCT06006806
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I
Interventions
Pencil Beam Scanning Proton Therapy
Radiation
Lead sponsor
Covenant Health Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 28, 2026, 8:39 PM EDT
Terminated Phase 3 Interventional Results available

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

NCT00925548
View directory record Official record
Conditions
Breast Cancer
Interventions
Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 28, 2026, 8:39 PM EDT